Attenuation of 7-ketocholesterol- and 7β-hydroxycholesterol-induced oxiapoptophagy by nutrients, synthetic molecules and oils: Potential for the prevention of age-related diseases.

7-Ketocholesterol 7β-Hydroxycholesterol Age-related diseases Endoplasmic reticulum Lysosome Mitochondria Nutrients Oxiapoptophagy Oxysterol Peroxisome

Journal

Ageing research reviews
ISSN: 1872-9649
Titre abrégé: Ageing Res Rev
Pays: England
ID NLM: 101128963

Informations de publication

Date de publication:
07 2021
Historique:
received: 01 02 2021
revised: 10 03 2021
accepted: 12 03 2021
pubmed: 29 3 2021
medline: 21 5 2021
entrez: 28 3 2021
Statut: ppublish

Résumé

Age-related diseases for which there are no effective treatments include cardiovascular diseases; neurodegenerative diseases such as Alzheimer's disease; eye disorders such as cataract and age-related macular degeneration; and, more recently, Severe Acute Respiratory Syndrome (SARS-CoV-2). These diseases are associated with plasma and/or tissue increases in cholesterol derivatives mainly formed by auto-oxidation: 7-ketocholesterol, also known as 7-oxo-cholesterol, and 7β-hydroxycholesterol. The formation of these oxysterols can be considered as a consequence of mitochondrial and peroxisomal dysfunction, leading to increased in oxidative stress, which is accentuated with age. 7-ketocholesterol and 7β-hydroxycholesterol cause a specific form of cytotoxic activity defined as oxiapoptophagy, including oxidative stress and induction of death by apoptosis associated with autophagic criteria. Oxiaptophagy is associated with organelle dysfunction and in particular with mitochondrial and peroxisomal alterations involved in the induction of cell death and in the rupture of redox balance. As the criteria characterizing 7-ketocholesterol- and 7β-hydroxycholesterol-induced cytotoxicity are often simultaneously observed in major age-related diseases (cardiovascular diseases, age-related macular degeneration, Alzheimer's disease) the involvement of these oxysterols in the pathophysiology of the latter seems increasingly likely. It is therefore important to better understand the signalling pathways associated with the toxicity of 7-ketocholesterol and 7β-hydroxycholesterol in order to identify pharmacological targets, nutrients and synthetic molecules attenuating or inhibiting the cytotoxic activities of these oxysterols. Numerous natural cytoprotective compounds have been identified: vitamins, fatty acids, polyphenols, terpenes, vegetal pigments, antioxidants, mixtures of compounds (oils, plant extracts) and bacterial enzymes. However, few synthetic molecules are able to prevent 7-ketocholesterol- and/or 7β-hydroxycholesterol-induced cytotoxicity: dimethyl fumarate, monomethyl fumarate, the tyrosine kinase inhibitor AG126, memantine, simvastatine, Trolox, dimethylsufoxide, mangafodipir and mitochondrial permeability transition pore (MPTP) inhibitors. The effectiveness of these compounds, several of which are already in use in humans, makes it possible to consider using them for the treatment of certain age-related diseases associated with increased plasma and/or tissue levels of 7-ketocholesterol and/or 7β-hydroxycholesterol.

Identifiants

pubmed: 33774195
pii: S1568-1637(21)00071-4
doi: 10.1016/j.arr.2021.101324
pii:
doi:

Substances chimiques

Hydroxycholesterols 0
Ketocholesterols 0
Oils 0
cholest-5-en-3 beta,7 alpha-diol 566-26-7
7-ketocholesterol O7676FE78M

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101324

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

T Nury (T)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France.

A Yammine (A)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France; Bioactive Molecules Research Laboratory, Doctoral School of Sciences and Technologies, Faculty of Sciences, Lebanese University, Fanar, Lebanon.

I Ghzaiel (I)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France; University Monastir, Faculty of Medicine, LR12ES05, Lab-NAFS 'Nutrition - Functional Food & Vascular Health', Monastir, Tunisia.

K Sassi (K)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France; University Tunis El Manar, Laboratory of Onco-Hematology (LR05ES05), Faculty of Medicine, 1007 Tunis, Tunisia.

A Zarrouk (A)

University Monastir, Faculty of Medicine, LR12ES05, Lab-NAFS 'Nutrition - Functional Food & Vascular Health', Monastir, Tunisia; University Sousse, Faculty of Medicine, Sousse, Tunisia.

F Brahmi (F)

University Abderrahmane Mira of Béjaia, Department of Food Sciences, Faculty of Natural and Life Sciences, Laboratory of Biophysics, Biochemistry, Biomathematics and Scientometry (3BS), Béjaia, Algeria.

M Samadi (M)

LCPMC-A2, ICPM, Dept of Chemistry, Univ. Lorraine, Metz Technopôle, Metz, France.

S Rup-Jacques (S)

LCPMC-A2, ICPM, Dept of Chemistry, Univ. Lorraine, Metz Technopôle, Metz, France.

D Vervandier-Fasseur (D)

Team OCS, Institute of Molecular Chemistry of University of Burgundy (ICMUB UMR CNRS 6302), University of Bourgogne Franche-Comté, Dijon, France.

J P Pais de Barros (JP)

Plateforme de Lipidomique - Univ. Bourgogne Inserm UMR1231, LabEx LipSTIC, UFR des Sciences de Santé, Dijon, France.

V Bergas (V)

Plateforme de Lipidomique - Univ. Bourgogne Inserm UMR1231, LabEx LipSTIC, UFR des Sciences de Santé, Dijon, France.

S Ghosh (S)

Department of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India.

M Majeed (M)

Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ, USA.

A Pande (A)

Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ, USA.

A Atanasov (A)

Department of Pharmacognosy, University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Vienna, Austria; Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzebiec, Poland; Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.

S Hammami (S)

University Monastir, Faculty of Medicine, LR12ES05, Lab-NAFS 'Nutrition - Functional Food & Vascular Health', Monastir, Tunisia.

M Hammami (M)

University Monastir, Faculty of Medicine, LR12ES05, Lab-NAFS 'Nutrition - Functional Food & Vascular Health', Monastir, Tunisia.

J Mackrill (J)

Department of Physiology, School of Medicine, University College Cork, Cork, Ireland.

B Nasser (B)

Laboratory of Biochemistry and Neurosciences, Department of Biology, University Hassan I, 26000 Settat, Morocco.

P Andreoletti (P)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France.

M Cherkaoui-Malki (M)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France.

A Vejux (A)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France. Electronic address: anne.vejux@u-bourgogne.fr.

G Lizard (G)

Team Bio-PeroxIL 'Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism' (EA 7270), University Bourgogne Franche-Comté (UBFC), Inserm, Dijon, France. Electronic address: gerard.lizard@u-bourgogne.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH